

2nd International Conference on

Retroviruses and Novel Drugs

June 30-July 01, 2016 Cape Town, South Africa

**Donatien Mavoungou***University of Health Science, Gabon, Africa*

Immunorex™ at the final stage of development for commercialization as a model of academic CRO/ industrial collaboration

Immunorex™ has a history of 40 years of studies on Monoamine oxidase (MOA) and DHEA in Cardiovascular diseases (High Blood Pressure) and in infection including HVI-1 known today to increase cardiovascular and cerebrovascular diseases via oxidative stress leading to inflammation and neuro-virulence. Immunorex™ is an immune-regulator with the capacity to block HIV-1 replication, to restore Th1 and Th2 equilibrium improving antibodies against HIV-Tat. It can also treat and prevent co-infections such as Tuberculosis, Malaria, Hepatitis B and C. The drug is an inhibitor of NADPH, the co-factor of G6PD resulting in the restoration of endothelial function producing Nitric oxide (NO) able to suppress neuro-inflammation and to influence Na/K Pump for blood pressure regulation. We want to present here Immunorex™ at its final stage of development for commercialization as a model of collaboration between Academic CRO and Industry for young scientists particularly in developing countries.

Biography

Donatien Mavoungou is the Director of the Research Center on Hormonal Pathologies (CRPH) Gabon, Invited Member at McGill University Aids Center (Montreal) and at Genomic Chair of Canada. He authored more than 150 publications. He discovered IMMUNOREX™ DM28 inhibiting HIV-1 replication. He is Professor of Biochemistry and Endocrinology at the University Of Health Science Libreville, Gabon. Field: HIV, Metabolic disorders, HAART, Hormonal Therapy. He received the Prize of the National Center for Scientific Research in 2009 and 2012. (Gabon). Blue Ribbon Presenter, recipient of the Glaxo Smith Klein Award at ISHIB, Orlando (USA, 2007). Member of WABT Academy.

crph2000@yahoo.fr